{"id":"esomeprazole-iv","safety":{"commonSideEffects":[{"rate":"5-10","effect":"Headache"},{"rate":"5-10","effect":"Diarrhea"},{"rate":"2-5","effect":"Nausea"},{"rate":"2-5","effect":"Abdominal pain"},{"rate":"2-5","effect":"Constipation"},{"rate":null,"effect":"Hypomagnesemia (with long-term use)"},{"rate":null,"effect":"C. difficile infection (with long-term use)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Esomeprazole is the active S-enantiomer of omeprazole. It binds to and inactivates the proton pump (H+/K+-ATPase) on the secretory surface of gastric parietal cells, preventing the final step of gastric acid production. This results in profound and sustained reduction of both basal and stimulated gastric acid secretion, providing rapid symptom relief and promoting healing of acid-related lesions.","oneSentence":"Esomeprazole is a proton pump inhibitor that suppresses gastric acid secretion by irreversibly blocking the H+/K+-ATPase enzyme in gastric parietal cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:46:32.847Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Gastroesophageal reflux disease (GERD)"},{"name":"Peptic ulcer disease"},{"name":"Zollinger-Ellison syndrome"},{"name":"Prevention of NSAID-induced ulcers"},{"name":"Stress ulcer prophylaxis in critically ill patients"}]},"trialDetails":[{"nctId":"NCT05582174","phase":"PHASE4","title":"PPI Infusion Versus Oral Acid Pump Inhibitors for Bleeding Peptic Ulcers","status":"RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2023-05-18","conditions":"Upper GI Bleeding, Proton Pump Inhibitors","enrollment":594},{"nctId":"NCT07399054","phase":"","title":"Efficacy and Safety of Esomeprazole 40 mg IV in Post-Surgical Patients Admitted to the ICU","status":"NOT_YET_RECRUITING","sponsor":"Asian Institute of Gastroenterology, India","startDate":"2026-01-15","conditions":"Stress Ulcers, Reflux Episodes","enrollment":50},{"nctId":"NCT06783257","phase":"PHASE2","title":"Phase II Clinical Study of Vonorasan Fumarate Injection in the Treatment of Peptic Ulcer Bleeding","status":"NOT_YET_RECRUITING","sponsor":"Shandong New Time Pharmaceutical Co., LTD","startDate":"2025-02","conditions":"Peptic Ulcer Bleeding","enrollment":150},{"nctId":"NCT05061563","phase":"PHASE1","title":"A Study to Learn How a Proton Pump Inhibitor Affects the Way Elinzanetant (BAY 3427080) Moves Into, Through and Out of the Body, and How Much of it Gets Absorbed by the Body When Taken as a Single and Small Radioactive Dose in Healthy Adults","status":"COMPLETED","sponsor":"Bayer","startDate":"2021-09-30","conditions":"Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men, Hot Flashes","enrollment":14},{"nctId":"NCT04407832","phase":"NA","title":"Comparing Two Doses of IV Esomeprazole After Successful Endoscopic Therapy","status":"WITHDRAWN","sponsor":"Changhua Christian Hospital","startDate":"2011-08","conditions":"Peptic Ulcer Bleeding","enrollment":""},{"nctId":"NCT02434978","phase":"NA","title":"Doppler-guided Endoscopic Treatment in Peptic Ulcer Bleeding","status":"UNKNOWN","sponsor":"Odense University Hospital","startDate":"2014-01","conditions":"Peptic Ulcer Bleeding","enrollment":125},{"nctId":"NCT02708355","phase":"PHASE4","title":"Pilot Study To Investigate The Association Between Acid Control And Heartburn Symptoms After Proton Pump Inhibitor Treatment","status":"COMPLETED","sponsor":"Pfizer","startDate":"2016-01","conditions":"Heartburn","enrollment":55},{"nctId":"NCT02157376","phase":"PHASE3","title":"Stress Ulcer Prophylaxis of Intravenous Esomeprazole in Chinese Seriously Ill Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-07","conditions":"Stress Ulcer Prophylaxis","enrollment":343},{"nctId":"NCT02307305","phase":"PHASE2","title":"Does Duloxetine Reduce Chronic Pain After Total Knee Arthroplasty?","status":"UNKNOWN","sponsor":"Hanyang University Seoul Hospital","startDate":"2014-08","conditions":"Neuropathic Pain","enrollment":168},{"nctId":"NCT01142245","phase":"PHASE3","title":"Effect of IV and Oral Esomeprazole in Prevention of Recurrent Bleeding From Peptic Ulcers After Endoscopic Therapy","status":"COMPLETED","sponsor":"Chinese University of Hong Kong","startDate":"2008-01","conditions":"Peptic Ulcer, Bleeding","enrollment":263},{"nctId":"NCT00660660","phase":"PHASE4","title":"Local Phase IV, Gastroesophageal Reflux Disease (GERD) Sleep Study US","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-04","conditions":"Gastroesophageal Reflux Disease","enrollment":276},{"nctId":"NCT01397084","phase":"PHASE4","title":"To Assess the Efficacy of Esomeprazole 20mg Once Daily in Subjects Who Still Had Heartburn After Receiving Rabeprazole","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2011-08","conditions":"Gastroesophageal Reflux Disease, GERD, Reflux Esophagitis","enrollment":107},{"nctId":"NCT01119768","phase":"PHASE4","title":"Esomeprazole Treatment Co-diagnosed Non Erosive Reflux Disease (NERD) and Chronic Gastritis Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-04","conditions":"Non Erosive Reflux Disease, Chronic Gastritis","enrollment":305},{"nctId":"NCT00164788","phase":"PHASE2","title":"A Comparison of Gastric pH Control With High Dose Intravenous or Oral Esomeprazole","status":"TERMINATED","sponsor":"Chinese University of Hong Kong","startDate":"2004-07","conditions":"Gastrointestinal Hemorrhage","enrollment":7},{"nctId":"NCT01275937","phase":"PHASE4","title":"A Double Blind Study Comparing Two Doses of IV Esomeprazole After Successful Endoscopic Therapy","status":"UNKNOWN","sponsor":"Taipei Medical University","startDate":"2011-08","conditions":"Upper Gastrointestinal Bleeding","enrollment":65},{"nctId":"NCT00343161","phase":"PHASE4","title":"Symptom Adapted Therapy in GERD Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-08","conditions":"Gastroesophageal Reflux Disease","enrollment":441},{"nctId":"NCT00626262","phase":"PHASE4","title":"Open, Randomized, Two Way Crossover Study Comparing the Effect of Esomeprazole Adminstered Orally and iv","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2002-07","conditions":"Gastroesophageal Reflux Disease","enrollment":60},{"nctId":"NCT00625495","phase":"PHASE4","title":"Study Comparing the Effects of Esomeprazole Adminstered Orally and Intravenously on Basal and Pentrigastrin-stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2002-09","conditions":"Gastroesophageal Reflux Disease","enrollment":60},{"nctId":"NCT00206050","phase":"PHASE4","title":"Study of Intragastric pH Profile After 5 Days Pantoprazole 40 mg iv Followed by Oral Esomeprazole 40 mg po or Oral Pantoprazole 40 mg po","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2004-09","conditions":"Healthy","enrollment":40},{"nctId":"NCT00637845","phase":"PHASE4","title":"Study Comparing Esomeprazole Magnesium 40mg Once Daily Versus Lansoprazole 30 mg Twice Daily in Symptom Control of Subjects With Persistent Gastrooesophageal Reflux Disease (GERD)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2002-06","conditions":"Heartburn, Gastroesophageal Reflux Disease","enrollment":248},{"nctId":"NCT00474019","phase":"PHASE1","title":"Phase 1 Pharmacokinetics of Intravenous Nexium in Children","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-10","conditions":"Pharmacokinetics","enrollment":42},{"nctId":"NCT00402259","phase":"PHASE3","title":"Efficacy and Safety Study of Esomeprazole vs Omeprazole to Treat Acute Non-Variceal Upper Gastrointestinal Bleeding","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-08","conditions":"Gastrointestinal Hemorrhage","enrollment":440},{"nctId":"NCT00272701","phase":"PHASE4","title":"Esomeprazole in PPI Failures - IMPROVE","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2005-12","conditions":"Gastroesophageal Reflux Disease","enrollment":450}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":54,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Esomeprazole IV","genericName":"Esomeprazole IV","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Esomeprazole is a proton pump inhibitor that suppresses gastric acid secretion by irreversibly blocking the H+/K+-ATPase enzyme in gastric parietal cells. Used for Gastroesophageal reflux disease (GERD), Peptic ulcer disease, Zollinger-Ellison syndrome.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}